Literature DB >> 33723241

Role of interleukins in the pathogenesis of pulmonary fibrosis.

Yi Xin She1, Qing Yang Yu1, Xiao Xiao Tang2.   

Abstract

Interleukins, a group of cytokines participating in inflammation and immune response, are proved to be involved in the formation and development of pulmonary fibrosis. In this article, we reviewed the relationship between interleukins and pulmonary fibrosis from the clinical, animal, as well as cellular levels, and discussed the underlying mechanisms in vivo and in vitro. Despite the effects of interleukin-targeted treatment on experimental pulmonary fibrosis, clinical applications are lacking and unsatisfactory. We conclude that intervening in one type of interleukins with similar functions in IPF may not be enough to stop the development of fibrosis as it involves a complex network of regulation mechanisms. Intervening interleukins combined with other existing therapy or targeting interleukins affecting multiple cells/with different functions at the same time may be one of the future directions. Furthermore, the intervention time is critical as some interleukins play different roles at different stages. Further elucidation on these aspects would provide new perspectives on both the pathogenesis mechanism, as well as the therapeutic strategy and drug development.

Entities:  

Year:  2021        PMID: 33723241      PMCID: PMC7960958          DOI: 10.1038/s41420-021-00437-9

Source DB:  PubMed          Journal:  Cell Death Discov        ISSN: 2058-7716


  102 in total

Review 1.  Is idiopathic pulmonary fibrosis an environmental disease?

Authors:  Varsha S Taskar; David B Coultas
Journal:  Proc Am Thorac Soc       Date:  2006-06

2.  Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis.

Authors:  Benjamin Ng; Jinrui Dong; Giuseppe D'Agostino; Sivakumar Viswanathan; Anissa A Widjaja; Wei-Wen Lim; Nicole S J Ko; Jessie Tan; Sonia P Chothani; Benjamin Huang; Chen Xie; Chee Jian Pua; Ann-Marie Chacko; Nuno Guimarães-Camboa; Sylvia M Evans; Adam J Byrne; Toby M Maher; Jiurong Liang; Dianhua Jiang; Paul W Noble; Sebastian Schafer; Stuart A Cook
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

3.  Increased bronchoalveolar lavage fluid CD1c expressing dendritic cells in idiopathic pulmonary fibrosis.

Authors:  M Tsoumakidou; K P Karagiannis; I Bouloukaki; S Zakynthinos; N Tzanakis; N M Siafakas
Journal:  Respiration       Date:  2009-06-24       Impact factor: 3.580

Review 4.  Therapeutic targets in idiopathic pulmonary fibrosis.

Authors:  Martin Kolb; Francesco Bonella; Lutz Wollin
Journal:  Respir Med       Date:  2017-08-01       Impact factor: 3.415

Review 5.  Tissue remodelling in pulmonary fibrosis.

Authors:  Lars Knudsen; Clemens Ruppert; Matthias Ochs
Journal:  Cell Tissue Res       Date:  2016-12-16       Impact factor: 5.249

6.  B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic mice.

Authors:  Mohammed Arras; Jamila Louahed; Vincent Simoen; Virginie Barbarin; Pierre Misson; Sybille van den Brûle; Monique Delos; Laurent Knoops; Jean-Christophe Renauld; Dominique Lison; François Huaux
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-19       Impact factor: 6.914

7.  IL-9 protects against bleomycin-induced lung injury: involvement of prostaglandins.

Authors:  Mohammed Arras; Jamila Louahed; Jean-François Heilier; Monique Delos; Frank Brombacher; Jean-Christophe Renauld; Dominique Lison; François Huaux
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

Review 8.  IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.

Authors:  Alexander R Moschen; Herbert Tilg; Tim Raine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

9.  Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis.

Authors:  Robert J J O'Donoghue; Darryl A Knight; Carl D Richards; Cecilia M Prêle; Hui Ling Lau; Andrew G Jarnicki; Jessica Jones; Steven Bozinovski; Ross Vlahos; Stefan Thiem; Brent S McKenzie; Bo Wang; Philip Stumbles; Geoffrey J Laurent; Robin J McAnulty; Stefan Rose-John; Hong Jian Zhu; Gary P Anderson; Matthias R Ernst; Steven E Mutsaers
Journal:  EMBO Mol Med       Date:  2012-06-08       Impact factor: 12.137

Review 10.  Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis.

Authors:  Hasancan Bilgili; Adam J Białas; Paweł Górski; Wojciech J Piotrowski
Journal:  J Clin Med       Date:  2019-08-16       Impact factor: 4.241

View more
  19 in total

1.  Differences and Similarities between the Lung Transcriptomic Profiles of COVID-19, COPD, and IPF Patients: A Meta-Analysis Study of Pathophysiological Signaling Pathways.

Authors:  Daniel Aguilar; Adelaida Bosacoma; Isabel Blanco; Olga Tura-Ceide; Anna Serrano-Mollar; Joan Albert Barberà; Victor Ivo Peinado
Journal:  Life (Basel)       Date:  2022-06-14

2.  Soluble ECM promotes organotypic formation in lung alveolar model.

Authors:  Jonard C Valdoz; Nicholas A Franks; Collin G Cribbs; Dallin J Jacobs; Ethan L Dodson; Connor J Knight; P Daniel Poulson; Seth R Garfield; Benjamin C Johnson; Brandon M Hemeyer; Miranda T Sudo; Jordan A Saunooke; Braden C Kartchner; Aubrianna Saxton; Mary L Vallecillo-Zuniga; Matheus Santos; Brandon Chamberlain; Kenneth A Christensen; Greg P Nordin; A Sampath Narayanan; Ganesh Raghu; Pam M Van Ry
Journal:  Biomaterials       Date:  2022-03-16       Impact factor: 15.304

Review 3.  The role of CXCL8 in chronic nonhealing diabetic foot ulcers and phenotypic changes in fibroblasts: a molecular perspective.

Authors:  Vikrant Rai; Rebecca Moellmer; Devendra K Agrawal
Journal:  Mol Biol Rep       Date:  2022-01-19       Impact factor: 2.316

4.  Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity.

Authors:  Mizanur Rahman; Martin Irmler; Sandeep Keshavan; Micol Introna; Johannes Beckers; Lena Palmberg; Gunnar Johanson; Koustav Ganguly; Swapna Upadhyay
Journal:  Viruses       Date:  2021-12-17       Impact factor: 5.048

5.  Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis.

Authors:  Carlos Eduardo Medina-De la Garza; Armando Salvador Flores-Torres; Marisela García-Hernández; María de Los Ángeles Castro-Corona
Journal:  Med Hypotheses       Date:  2022-01-25       Impact factor: 1.538

Review 6.  Obesity and the Development of Lung Fibrosis.

Authors:  Xia Guo; Christudas Sunil; Guoqing Qian
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

Review 7.  The Crucial Role of NLRP3 Inflammasome in Viral Infection-Associated Fibrosing Interstitial Lung Diseases.

Authors:  Wiwin Is Effendi; Tatsuya Nagano
Journal:  Int J Mol Sci       Date:  2021-09-28       Impact factor: 5.923

Review 8.  Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications.

Authors:  Jamal Majidpoor; Keywan Mortezaee
Journal:  Biomed Pharmacother       Date:  2021-11-12       Impact factor: 7.419

Review 9.  Irreversibility of Pulmonary Fibrosis.

Authors:  Qing Yang Yu; Xiao Xiao Tang
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

Review 10.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.